mutation class

Small Mutation

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

40 sites for NCT04765059

EGFR Mutation

Non-Squamous Non-Small Cell Lung Carcinoma

carboplatin, +3 more drugs

chemotherapy, +1 more type

Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

61 sites for NCT03318939

EGFR A763_Y764insFQEA, +31 more biomarkers

Non-Small Cell Lung Carcinoma

poziotinib

targeted therapy

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

81 sites for NCT02609776

EGFR A763_Y764insFQEA, +19 more biomarkers

Lung Adenocarcinoma, +2 more conditions

amivantamab, +3 more drugs

chemotherapy, +1 more type

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

71 sites for NCT04077463

EGFR Mutation

Non-Small Cell Lung Carcinoma

amivantamab, +3 more drugs

chemotherapy, +1 more type

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

1 site for NCT04958811

EGFR Mutation, +2 more biomarkers

Non-Squamous Non-Small Cell Lung Carcinoma

atezolizumab, +2 more drugs

immunotherapy, +1 more type

AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

10 sites for NCT04413201

EGFR Mutation

Non-Squamous Non-Small Cell Lung Carcinoma

afatinib, +2 more drugs

targeted therapy

patritumab deruxtecan

EGFR Mutation

Non-Small Cell Lung Carcinoma

Locally advanced, +1 more state

Subsequent line

patritumab deruxtecan

chemotherapy, +1 more type